Incretin therapies have created a breakthrough in #obesity treatment. This success has been driven by hunger suppression that leads to noticeable weight loss, not only reducing weight but also decreasing comorbidities like heart failure and chronic kidney disease. However,

With the rate of #obesity doubling in just 32 years, this growing population has diverse needs related to their condition and treatment. $SKYE remains focused on new mechanisms and drugs that have the potential to enhance therapeutic approaches and improve health outcomes.

The increase in #obesity rates is impacting people of all ages, further cementing the need for better treatment, improved harm reduction, and healthier weight loss options. Learn more about how $SKYE is dedicated to developing new treatments that help reduce excess body fat and

We can’t solve tomorrow’s #obesity crisis with only yesterday’s solutions. Here's why Skye is committed to developing next-generation drugs to treat obesity and other metabolic diseases. To explore our technology, visit our website here: $SKYE

Why is Skye all in on #nimacimab?. Here’s some background information on how we’re working towards advancing obesity treatment with nimacimab, including our clinical milestones, ongoing Phase 2 study, and investment in this potential paradigm shift in #obesity therapy. For more

What makes our approach to CB1 different?. Today, we explore some of the history of CB1 inhibitor use, our approach using nimacimab, pre-clinical data suggestions, and future potential. For more details on our pipeline, please visit our website:

Skye CEO, Punit Dhillon, appeared on The Bio Report podcast to discuss using CB1 as a target for #obesity treatment, our current pipeline, and research using nimacimab, including its combination potential with GLP-1 agonists and other therapeutic approaches. Listen to the full

Chapter 3 of The Anatomy of Progress covers the market opportunity for nimacimab, where Skye’s Chief Operating Officer, Tu Diep, MSc, discusses input from #obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with the target product profile

Chapter 2 of The Anatomy of Progress reviews Skye’s current clinical activity and near-term path to our Phase 2a data, with extensive commentary from Skye’s Chief Medical Officer, Puneet S. Arora, MD, MS, FACE. Watch the full video here: #obesity.$SKYE

In Chapter 1 of The Anatomy of Progress, we review Skye’s highly peripherally-restricted CB1 inhibitor and its advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with our recent preclinical data. View the full video here:

In the introduction to The Anatomy of Progress, we highlight Skye’s positioning and progress in therapeutic drug development, exploring the promise of CB1 inhibition, differentiation of nimacimab’s allosteric modulation, and more. View the full overview through our YouTube

Members of the Skye leadership team will participate in the 3rd Annual Piper Sandler Obesity Symposium, Thursday, June 26th. This 25-minute fireside chat will include CEO Punit Dhillon, CMO Puneet S. Arora, MD, MS, FACE, and CSO Chris Twitty, PhD. We look forward to sharing

Punit Dhillon, Puneet Arora, MD, FACE, and Chris Twitty, PhD, participated in the non-incretin therapeutics panel at Evercore’s investor-focused #obesity event, alongside notable obesity physicians Helena Rodbard, MD, FACP, MACE, and Sean Wharton, MD, PharmD. From reviewing.

During his Innovation Hub presentation during the @AmDiabetesAssn's 85th Scientific Sessions, Skye's Chief Scientific Officer, Chris Twitty, PhD, highlighted nimacimab’s differentiated characteristics, including meaningful weight loss data from a pre-clinical diet-induced obesity.

Today, we announced the debut of our “Anatomy of Progress” nimacimab development update video series, along with highlighting preclinical data during multiple presentations and panels during the @AmDiabetesAssn's 85th Scientific Sessions. Please see today's release for more

With a growing population of patients who have diverse needs related to #obesity, we're focused on developing new treatments to help reduce excess body fat and improve metabolic health. Learn more about the current need and our pipeline: $SKYE

Skye has been selected to present expanded preclinical CB1 antibody data at the @AmDiabetesAssn's 85th Scientific Sessions. To learn more about the three different presentations Skye will be involved in, please see today's release: $SKYE

Our highly experienced team is driving forward our vision of significantly improving #metabolichealth outcomes. Learn more about how we're looking beyond the horizons of today’s #obesity therapeutics with the goal of achieving healthier, sustainable outcomes:

Although modern life has reduced the risk of food shortages for many, our bodies still store energy as fat, a trait shaped by our evolutionary past that can result in systemic inflammation and chronic disease. In today's video, Chief Medical Officer Dr. Puneet Arora, MD, MS,

Harnessing the therapeutic potential of nimacimab and CB1 inhibition, Skye aims to redefine obesity treatment through sustainable weight loss with improved safety and efficacy. Want to learn more about why we’ve chosen CB1? Explore our current pipeline here: